Picture loading failed.

Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bamlanivimab (INN, codenamed LY-CoV555) is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The drug was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and 950,000 doses have been bought by the US government as of December 2020. In April 2021, the EUA was revoked.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-045-1mg 1mg 3090
GMP-Bios-ab-045-10mg 10mg Inquiry
GMP-Bios-ab-045-100mg 100mg Inquiry
GMP-Bios-ab-045-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody
INN Name Bamlanivimab
TargetSARS-CoV-2 Spike
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure7l3n:DE/7kmg:AB:DE
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesAbcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases
Conditions ApprovedCOVID-19
Conditions Activena
Conditions Discontinuedna
Development TechBaiting from convalescent human B-cells